Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.69 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7104126 | 0.89 | CHRNB2 (0.67) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL23067927 | 0.84 | CHRNB2 (0.74) | CHRNB2CHRNA4KMT2ADRD4DRD2 | |
| SCHEMBL30756757 | 0.84 | CHRNB2 (0.74) | CHRNB2CHRNA4KMT2ADRD4DRD2 | |
| SCHEMBL6254868 | 0.83 | CHRNB2 (0.90) | CHRNB2CHRNA4 | |
| SCHEMBL30756567 | 0.81 | CHRNB2 (1.00) | CHRNB2CHRNA4 | |
| SCHEMBL7101352 | 0.81 | CHRNB2 (1.00) | CHRNB2CHRNA4 | |
| SCHEMBL422229 | 0.81 | CYP2C9 (0.70) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL18995938 | 0.81 | CHRNB2 (0.69) | CHRNB2CHRNA4KMT2A | |
| SCHEMBL7103959 | 0.80 | DRD4 (0.64) | CHRNB2CHRNA4SCN8ADRD4DRD2 | |
| SCHEMBL7102684 | 0.80 | DRD2 (0.42) | CHRNB2CHRNA4CYP2D6CYP2C19SCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003500393-A | — | — | 2003-01-07 | — | — | JP | claimed |
| US-6441006-B2 | NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-08-27 | — | — | US | claimed |
| EP-1185513-A2 | ARYL SUBSTITUTED ALKYLAMINES CAPABLE OF ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2002-03-13 | — | — | EP | claimed |
| US-20010031771-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. | 2001-10-18 | — | — | US | claimed |
| US-20010014691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. | 2001-08-16 | — | — | US | claimed |
| WO-2000071520-A2 | ARYL SUBSTITUTED ALKYLAMINES CAPABLE OF ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2000-11-30 | — | — | WO | claimed |
| US-6627648-B1 | Relevant nicotinic receptor subtypes to any significant degree. central nervous system disorders, are treated by administering to a patient in need thereof amine derivatives | TARGACEPT, INC. | 2003-09-30 | — | — | US | disclosed |
| US-6441006-B2 | NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-08-27 | — | — | US | disclosed |
| US-6441006-B2 | NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-08-27 | — | — | US | disclosed |
| EP-1185513-A2 | ARYL SUBSTITUTED ALKYLAMINES CAPABLE OF ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| US-20010031771-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. | 2001-10-18 | — | — | US | disclosed |
| US-20010014691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. | 2001-08-16 | — | — | US | disclosed |
| US-20010014691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. | 2001-08-16 | — | — | US | disclosed |
| WO-2000071520-A2 | ARYL SUBSTITUTED ALKYLAMINES CAPABLE OF ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031771-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | PNMT, TPMT, HTR7 | CHRNB2 98/4885CHRNA4 32/4885CYP3A4 183/4885 |
| US-20010014691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | PNMT, HNMT, CHRM3 | CHRNB2 32/4885CHRNA4 34/4885CYP3A4 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.